Cetera Investment Advisers Acquires 877 Shares of argenx SE (NASDAQ:ARGX)

Cetera Investment Advisers increased its holdings in argenx SE (NASDAQ:ARGX - Free Report) by 27.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 4,127 shares of the company's stock after purchasing an additional 877 shares during the quarter. Cetera Investment Advisers' holdings in argenx were worth $2,538,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently bought and sold shares of the company. Bayesian Capital Management LP boosted its stake in shares of argenx by 38.0% during the 4th quarter. Bayesian Capital Management LP now owns 621 shares of the company's stock valued at $382,000 after purchasing an additional 171 shares in the last quarter. BNP Paribas Financial Markets boosted its position in argenx by 138.4% during the 4th quarter. BNP Paribas Financial Markets now owns 10,232 shares of the company's stock valued at $6,293,000 after acquiring an additional 5,940 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in shares of argenx by 10.0% during the 4th quarter. Ameriprise Financial Inc. now owns 7,013 shares of the company's stock worth $4,313,000 after acquiring an additional 639 shares during the period. Acuta Capital Partners LLC raised its position in shares of argenx by 17.1% in the 4th quarter. Acuta Capital Partners LLC now owns 6,910 shares of the company's stock worth $4,250,000 after acquiring an additional 1,010 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec bought a new position in shares of argenx in the 4th quarter worth approximately $17,158,000. Hedge funds and other institutional investors own 60.32% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ARGX. Oppenheimer upped their price target on argenx from $704.00 to $708.00 and gave the stock an "outperform" rating in a research note on Friday, May 9th. JMP Securities set a $699.00 target price on shares of argenx in a research report on Wednesday, May 14th. Wells Fargo & Company increased their price target on shares of argenx from $723.00 to $741.00 and gave the stock an "overweight" rating in a research note on Friday, February 28th. William Blair reissued an "outperform" rating on shares of argenx in a research note on Friday, February 28th. Finally, Guggenheim decreased their target price on shares of argenx from $1,100.00 to $1,065.00 and set a "buy" rating for the company in a research note on Friday, May 9th. One equities research analyst has rated the stock with a hold rating, twenty have issued a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Buy" and a consensus price target of $698.11.

argenx Stock Up 1.1%

ARGX traded up $6.64 during midday trading on Wednesday, hitting $584.95. 434,704 shares of the company traded hands, compared to its average volume of 325,477. The company's 50-day moving average is $591.30 and its 200 day moving average is $613.17. The firm has a market capitalization of $35.72 billion, a PE ratio of -664.72 and a beta of 0.57. argenx SE has a 52 week low of $356.38 and a 52 week high of $678.21.

argenx (NASDAQ:ARGX - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported $2.58 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.26. The company had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $748.34 million. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. On average, sell-side analysts predict that argenx SE will post 3.13 earnings per share for the current fiscal year.

argenx Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.